Last reviewed · How we verify
Anadrol-50 (OXYMETHOLONE)
Anadrol-50 (OXYMETHOLONE) is a small molecule oxymetholone drug developed by MEDA PHARMS and currently owned by Pharmobedient. It targets the androgen receptor and was FDA-approved in 1972 for the treatment of aplastic anemia, congenital hypoplastic anemia, and hypoplastic anemia. As an off-patent medication, Anadrol-50 is no longer protected by patents, and its commercial status is generic. Key safety considerations include the potential for liver damage and other adverse effects. Anadrol-50 is a potent anabolic steroid that promotes muscle growth and red blood cell production.
At a glance
| Generic name | OXYMETHOLONE |
|---|---|
| Sponsor | Pharmobedient |
| Drug class | oxymetholone |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1972 |
Approved indications
- Aplastic anemia
- Congenital hypoplastic anemia
- Hypoplastic anemia
Common side effects
Key clinical trials
- VR&R: Providing Caregiver Respite by Managing BPSDs and Improving QoL in People with Dementia Using Immersive VR-Therapy (NA)
- Virtual Reality as a Postoperative Pain Management Adjunct in Older Adults: An Acceptability and Feasibility Study (NA)
- Carbidopa for the Treatment of Excessive Blood Pressure Variability (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anadrol-50 CI brief — competitive landscape report
- Anadrol-50 updates RSS · CI watch RSS
- Pharmobedient portfolio CI